Dallas, TX Clinical Trials Report — June 2026

For Dallas residents considering participation in clinical research, June 2026 presents both urgent opportunities and significant new avenues for contributing to medical science. Across Dallas, TX, a number of trials are nearing their enrollment deadlines, making prompt action essential for interested individuals.

A total of 89 clinical trials are slated to conclude within the next 90 days. This urgency is particularly relevant for healthy volunteers, as 15 of these rapidly closing studies are still actively seeking participants without specific health conditions. These trials offer a chance to contribute to medical advancements before their enrollment windows close.

Act Now: Trials Nearing Conclusion

Patients managing specific health conditions also face impending deadlines to join research. Trials focused on various conditions are among those with limited time remaining for enrollment. Conditions with trials closing soon include:

• Heart failure (3 trials)
• Renal cell carcinoma (3 trials)
• Duchenne muscular dystrophy (3 trials)
• Prostate cancer (3 trials)
• Hypertension (3 trials)
• Advanced solid tumor (3 trials)
• Breast cancer (3 trials)
• Obesity (2 trials)
• Advanced breast cancer (2 trials)

For healthy individuals, 3 trials specifically for healthy volunteers are also closing soon, providing a direct opportunity to participate in research without a pre-existing condition.

New Research Opportunities in Dallas

This month, Dallas saw the opening of 24 new clinical trials, a decrease from the 37 trials that launched in May 2026. Despite this slight dip, the city continues to host a robust research landscape, with a total of 1,472 clinical trials currently recruiting across 665 research facilities.

June brings several high-profile new trials to Dallas, including significant Phase 3 studies from major sponsors. These trials offer participants the chance to engage with cutting-edge treatments and diagnostic approaches across a range of health challenges.

• AstraZeneca is initiating a notable Phase 3 study, NCT07667803, "A Master Protocol to Investigate Efficacy and Safety of Elecoglipron in Participants With Obesity or Overweight With or Without T2DM." This global, randomized, double-blind study aims for 4,500 participants to assess the efficacy and safety of elecoglipron compared with placebo.
• Also from AstraZeneca, NCT07662213, "A Study to Find Out if the Study Drug Elecoglipron Helps Adults With Type 2 Diabetes Mellitus by Comparing it With Semaglutide," is a Phase 3 trial seeking 1,200 participants. This study will evaluate elecoglipron's efficacy, safety, and tolerability against oral semaglutide in adults with Type 2 Diabetes Mellitus.
• Kallyope Inc. is sponsoring NCT07645924, "A Study to Evaluate the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine." This double-blind, randomized, multicenter Phase 3 trial aims for 1,800 participants to evaluate the efficacy, safety, and tolerability of elismetrep compared with placebo in the acute treatment of migraine.
• Another study from Kallyope Inc. is NCT07674654, "A Long-Term Safety Study of Elismetrep (K-304) in the Acute Treatment of Migraine," a Phase 3 trial with 1,000 participants. This study will evaluate the long-term safety and tolerability of intermittent use of elismetrep for migraine attacks.
• Convergent Genomics, Inc. is leading NCT07673016, "Specimen Collection for Validation of UroAmp: A Next Generation Sequencing Platform for Detection and Surveillance of Bladder Cancer." This prospective, multicenter observational study will collect urine and tumor biospecimens and associated clinical data from 2,500 patients undergoing evaluation, treatment, or surveillance for urothelial carcinoma.
• Texas A&M University is sponsoring NCT07659821, "Harvesting Health: Advancing Nutrition and Wellness for Moms and Babies," a randomized controlled trial aiming for 800 participants. This study assesses whether a personalized food kit for pregnant women improves diet quality and enhances pregnancy and birth outcomes.

New trials this month are exploring a range of conditions, with the most frequent being migraine (2 trials). Other conditions include advanced solid tumor, colorectal cancer, various forms of bipolar disorder, bladder cancer, brain injuries, and castrate sensitive prostate cancer, each with 1 new trial. Drug trials account for the largest share of new studies, with 13 new drug trials, followed by 7 other types of studies and 3 behavioral studies.

Opportunities for Healthy Volunteers

For individuals without a specific medical condition, there are significant opportunities to contribute to research in Dallas. A total of 4 of the 24 new trials launched this month are actively seeking healthy volunteers. Across Dallas, a total of 125 clinical trials are currently recruiting healthy participants, providing numerous avenues for those interested in supporting medical research.

Dallas's Leading Research Facilities

Dallas is home to some of the region's leading research institutions, which consistently run a high volume of clinical trials. These facilities are key destinations for individuals seeking to participate in medical research:

• University of Texas Southwestern Medical Center (176 trials)
• UT Southwestern Medical Center (157 trials)
• UT Southwestern/Simmons Cancer Center-Dallas (87 trials)
• University of Texas Southwestern (58 trials)
• Baylor University Medical Center (36 trials)
• Parkland Memorial Hospital (32 trials)
• Mary Crowley Cancer Research (28 trials)
• Medical City Dallas Hospital (27 trials)
• The University of Texas Southwestern Medical Center (23 trials)
• UT Southwestern Simmons Cancer Center - RedBird (23 trials)
• Retina Foundation of the Southwest (20 trials)

The various entities of the University of Texas Southwestern Medical Center collectively lead the city in clinical research, specializing in a wide array of medical fields. Baylor University Medical Center and Parkland Memorial Hospital also contribute significantly to the local research landscape, offering diverse trial options.

Broadening Your Search: Nearby Texas Options

While Dallas offers a vast array of clinical trial opportunities, individuals may also find options in nearby communities within Texas. Cities with active trials include Houston (46 trials), San Antonio (28 trials), Austin (16 trials), Fort Worth (5 trials), McKinney (4 trials), Plano (3 trials), Brownsville (3 trials), and El Paso (3 trials).

Participation in clinical trials is open to a diverse range of individuals. Of the 24 new trials launched this month, 21 include older adults, ensuring that senior populations have ample opportunity to contribute to medical science. Additionally, 1 new trial includes children, 2 are female-only, and 2 are male-only. Industry sponsors are driving a significant portion of new research in Dallas, with 12 new industry-sponsored trials this month, compared to 11 from academic institutions. Notable sponsors include University of Texas Southwestern Medical Center (3 trials), AstraZeneca (3 trials), Texas A&M University (2 trials), and Kallyope Inc. (2 trials).

As we move through June, Dallas's robust research community will continue to drive medical innovation, offering diverse opportunities for individuals to contribute to the future of healthcare and potentially benefit from cutting-edge treatments.